Our lines of work are focused on the diagnosis of solid tumours, mainly in NSCLC and transferring scientific advances in the area of oncology in the healthcare setting. • Study genomic and molecular data to guide the design of clinical trials and the development of biomarkers. • Based on preclinical cancer models, we study molecular mechanisms of sensitivity and pharmacological resistance. • Validate novel molecular technologies to streamline the screening of targetable biomarkers in non-small cell lung cancer (NSCLC). • Identification of novel fusion gene variants in NSCLC: phenotypic characterization of targeted population and prospective clinical validation of their predictive value to targeted treatments.